Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

795.97 +40.97 (+5.43%)
Streaming Delayed Price Updated: 1:08 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Capturing Consumer Spending on Health Care with XLV
Capturing Consumer Spending on Health Care with XLV 
Via News Direct
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Altimmune has a modest market cap but an incredibly promising GLP-1 drug. 
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both. 
Via The Motley Fool
SPDR ETF Report For Friday, April 19
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, April 19. 
Via Talk Markets
Topics ETFs
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
The Nasdaq and S&P 500 tumbled below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
Eli Lilly and Co's Options Frenzy: What You Need to Know
Via Benzinga
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
Investors should not ignore these highly rated stocks to buy now because they deserve their reputation as the market heats up. 
Via InvestorPlace
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025. 
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder. 
Via InvestorPlace
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
These stocks have taken different paths to where they are today, but both have been exceptional investments. 
Via The Motley Fool
Top Research Reports For Eli Lilly, Linde & Caterpillar
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Linde plc (LIN) and Caterpillar Inc. (CAT). 
Via Talk Markets
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals. 
Via The Motley Fool
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea. 
Via Investor's Business Daily
Nasdaq 100 Forecast: QQQ Inches Higher Ahead Of Fed Speakers
US stocks are pointing to a higher start, with corporate updates in focus, after Federal Reserve chair Jerome Powell raised doubts over the Fed's ability to cut rates this year. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show
Goundbreaking results in treating obstructive sleep apnea (OSA) with Eli Lilly's tirzepatide. See significant reductions in apnea-hypopnea index (AHI) and body weight, offering hope for OSA patients. 
Via Benzinga
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
Via InvestorPlace
Topics ETFs
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction. 
Via Benzinga
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28. 
Via Talk Markets
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. 
Via InvestorPlace
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
Novo Nordisk Arms Wegovy to Be a Triple Threat
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders 
Via MarketBeat
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great. 
Via The Motley Fool
This Vanguard ETF Has Skyrocketed 40% in 12 Months. Is It a No-Brainer Buy Right Now?
You can own a basket of tremendously successful stocks with this ETF. 
Via The Motley Fool
Topics ETFs
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A powerfully bullish new analyst take on the company helped it rally on the market. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.